Lonza

LONN.SWPhase 1

Basel, Switzerlandlonza.com

Founded in 1897 and headquartered in Basel, Switzerland, Lonza has evolved from a chemical company into a leading global CDMO serving the pharmaceutical and biotech industries. The company operates through two main divisions: Biologics (mammalian and microbial manufacturing) and Cell & Gene Technologies (viral vectors, cell therapy manufacturing). With over 17,000 employees across 30+ countries, Lonza generates approximately $6+ billion in annual revenue and trades on the Swiss stock exchange.

Market Cap

$41.6B

Employees

15,000-20,000

Focus

AntibodiesBiologicsSmall Molecules

LONN.SW · Stock Price

USD 466.70187.90 (-28.70%)

Historical price data

AI Company Overview

Technology Platform

Lonza operates as a leading CDMO providing integrated development and manufacturing services across biologics, cell & gene therapies, and small molecules, with specialized platforms for mammalian cell culture, viral vector production, and automated cell therapy processing.

Pipeline Snapshot

1 drug in pipeline

Drug	Indication	Stage
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + Be...	Metastatic Pancreatic Ductal Adenocarcinoma	Phase 1

Funding History

IPOUndisclosedUndisclosedJun 15, 1999

Opportunities

Lonza is positioned to capitalize on the growing demand for biologics manufacturing, the rapid expansion of cell and gene therapy approvals, and increasing pharmaceutical outsourcing trends.

The company's investments in next-generation manufacturing technologies and global capacity expansion create significant growth potential.

Risk Factors

Key risks include intense competition from other CDMOs, regulatory compliance challenges across multiple jurisdictions, potential customer concentration issues, and the need for continuous technology investment to maintain competitive positioning in rapidly evolving therapeutic areas.

Competitive Landscape

Lonza competes with major CDMOs including Catalent, Thermo Fisher Scientific, Samsung Biologics, and WuXi Biologics. The company differentiates through its integrated end-to-end platform, specialized cell & gene therapy capabilities, and strong relationships with major pharmaceutical partners built over decades of operation.

Publications

Patents

Pipeline